Terms: = Prostate cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551
222 results:
1. Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker.
Zainodini N; Abolhasani M; Mohsenzadegan M; Farajollahi MM; Rismani E
J Cancer Res Clin Oncol; 2024 Mar; 150(3):165. PubMed ID: 38546751
[TBL] [Abstract] [Full Text] [Related]
2. Novel estrogen receptor β/histone deacetylase dual-targeted near-infrared fluorescent probes as theranostic agents for imaging and treatment of prostate cancer.
He P; Yu H; Deng X; Xin L; Xu B; Zhou HB; Dong C
Eur J Med Chem; 2024 Mar; 268():116236. PubMed ID: 38367494
[TBL] [Abstract] [Full Text] [Related]
3. prostate cancer Risk Stratification by Simple Scoring of the Current pT3 Lesions: A Proposal for a New Pathologic T-Staging System.
Miyamoto H; Teramoto Y; Numbere N; Wang Y; Joseph JV
Mod Pathol; 2024 Mar; 37(3):100429. PubMed ID: 38266919
[TBL] [Abstract] [Full Text] [Related]
4. Modular Design Platform for Activatable Fluorescence Probes Targeting Carboxypeptidases Based on ProTide Chemistry.
Kuriki Y; Sogawa M; Komatsu T; Kawatani M; Fujioka H; Fujita K; Ueno T; Hanaoka K; Kojima R; Hino R; Ueo H; Ueo H; Kamiya M; Urano Y
J Am Chem Soc; 2024 Jan; 146(1):521-531. PubMed ID: 38110248
[TBL] [Abstract] [Full Text] [Related]
5. Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy: An AIRO multi-institutional study.
Leonardi MC; Pepa M; Zaffaroni M; Vincini MG; Luraschi R; Vigorito S; Morra A; Dicuonzo S; Mazzola GC; Gerardi MA; Zerella MA; Cante D; Petrucci E; Borzì G; Marrocco M; Chieregato M; Iadanza L; Lobefalo F; Valenti M; Cavallo A; Russo S; Guernieri M; Malatesta T; Meaglia I; Liotta M; Palumbo I; Marcantonini M; Mezzenga E; Falivene S; Arrichiello C; Barbero MP; Ivaldi GB; Catalano G; Vidali C; Giannitto C; Ciabattoni A; Meattini I; Aristei C; Orecchia R; Cattani F; Jereczek-Fossa BA
Tumori; 2023 Dec; 109(6):570-575. PubMed ID: 37688419
[TBL] [Abstract] [Full Text] [Related]
6. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer.
Celada SI; Li G; Celada LJ; Lu W; Kanagasabai T; Feng W; Cao Z; Salsabeel N; Mao N; Brown LK; Mark ZA; Izban MG; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Wang X; Chen Z
Mol Oncol; 2023 Oct; 17(10):2126-2146. PubMed ID: 37491794
[TBL] [Abstract] [Full Text] [Related]
7. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
[TBL] [Abstract] [Full Text] [Related]
8. Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant prostate cancer.
Sperger JM; Helzer KT; Stahlfeld CN; Jiang D; Singh A; Kaufmann KR; Niles DJ; Heninger E; Rydzewski NR; Wang L; Wang L; Yang R; Ren Y; Engle JW; Huang P; Kyriakopoulos CE; Slovin SF; Soule HR; Zhao SG; Kohli M; Tagawa ST; Cai W; Dehm SM; Lang JM
Clin Cancer Res; 2023 Jun; 29(12):2324-2335. PubMed ID: 36939530
[TBL] [Abstract] [Full Text] [Related]
9. Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in prostate cancer by Low-Intensity Focused Ultrasound.
Dai J; Wu Y; Chen Z; Xiao L; Zhang W; Cao Y
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614265
[TBL] [Abstract] [Full Text] [Related]
10. Synthesis, Solid State Structure, and Cytotoxic Activity of a Complex Dimer of Yttrium with Anthranilic Acid against cancer Cells.
Zidan ASA; Ibrahim ABM; Aly AAM; Mosbah HK; Mayer P; Saber SH
Biol Trace Elem Res; 2023 Oct; 201(10):4688-4696. PubMed ID: 36602747
[TBL] [Abstract] [Full Text] [Related]
11. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S
Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504
[TBL] [Abstract] [Full Text] [Related]
12. The Effectiveness of prostate Imaging and Reporting and Data System Version 2 in the Diagnosis of prostate cancer with Screening Parameters Correlation.
Arik ŞB; Güvenir D; Bozlar U; Taşar M; Turgut B
Arch Esp Urol; 2022 Jun; 75(5):416-422. PubMed ID: 35983812
[TBL] [Abstract] [Full Text] [Related]
13. Is PSA Still the Best Predictor for Biochemical Recurrence after Radical prostatectomy in High-Risk prostate cancer?
Akan S; Güner ND; Ediz C; Şahin A; Verit A
J Invest Surg; 2022 Oct; 35(10):1733-1738. PubMed ID: 35876092
[TBL] [Abstract] [Full Text] [Related]
14. Estrogen receptor β-targeted hypoxia-responsive near-infrared fluorescence probes for prostate cancer study.
Xie B; Meng Q; Yu H; Shen K; Cheng Y; Dong C; Zhou HB
Eur J Med Chem; 2022 Aug; 238():114506. PubMed ID: 35671592
[TBL] [Abstract] [Full Text] [Related]
15. GRP78-targeted and doxorubicin-loaded nanodroplets combined with ultrasound: a potential novel theranostics for castration-resistant prostate cancer.
Zhao Y; Shi D; Shang M; Sun X; Guo L; Meng D; Liu X; Zhou X; Li J
Drug Deliv; 2022 Dec; 29(1):203-213. PubMed ID: 34985396
[TBL] [Abstract] [Full Text] [Related]
16. Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation.
Witt JH; Friedrich M; Jandrig B; Porsch M; Baumunk D; Liehr UB; Wendler JJ; Schostak M
BJU Int; 2022 Oct; 130(4):454-462. PubMed ID: 34657365
[TBL] [Abstract] [Full Text] [Related]
17. PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
Dai L; Shen G; Wang Y; Yang P; Wang H; Liu Z
J Mater Chem B; 2021 Jan; 9(4):1151-1161. PubMed ID: 33434248
[TBL] [Abstract] [Full Text] [Related]
18. The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.
Noto FK; Sangodkar J; Adedeji BT; Moody S; McClain CB; Tong M; Ostertag E; Crawford J; Gao X; Hurst L; O'Connor CM; Hanson EN; Izadmehr S; Tohmé R; Narla J; LeSueur K; Bhattacharya K; Rupani A; Tayeh MK; Innis JW; Galsky MD; Evers BM; DiFeo A; Narla G; Jamling TY
PLoS One; 2020; 15(10):e0240169. PubMed ID: 33027304
[TBL] [Abstract] [Full Text] [Related]
19. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1' region.
Kwon H; Lim H; Ha H; Choi D; Son SH; Nam H; Minn I; Byun Y
Bioorg Chem; 2020 Nov; 104():104304. PubMed ID: 33011530
[TBL] [Abstract] [Full Text] [Related]
20. Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors.
Kasprzak A; Szaflarski W
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977489
[TBL] [Abstract] [Full Text] [Related]
[Next]
